Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417270 · ClinicalTrials.gov registry record · NA
Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge
A NA study, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT04417270 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 52 participants.
The verdict
NCT04417270, a NA study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The FDA has provided an emergency waiver for the use of non-invasive continuous glucose monitors (CGM) in hospitals, so frontline health care providers (in hospitals) can remotely monitor patients with diabetes thus reducing patient's discomfort, limiting exposure to COVID-19 and preserving critical personal protective equipment (PPE). The FreeStyle Libre 14-day system is a continuous glucose monitoring system consisting of a handheld reader (smart phone may be used) and a sensor applied with adhesive to back of the upper arm. In order to evaluate the reliability of the Freestyle Libre CGM for in-patient use, we propose a study which will examine the correlation between the libre CGM data and capillary blood glucose test - the current standard of care taken by the Accuchek Inform II platform.
Interventions
- DEVICE Freestyle Libre 14 day CGM system
- DEVICE Accuchek Inform II platform
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2020-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04417270
The ClinicalTrials.gov registry entry for NCT04417270 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Freestyle Libre 14 day CGM system is the first listed.
NCT04417270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04417270 about?
NCT04417270 is a clinical study titled "Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge". The FDA has provided an emergency waiver for the use of non-invasive continuous glucose monitors (CGM) in hospitals, so frontline health care providers (in hospitals) can remotely monitor patients with diabetes thus reducing patient's discomfort, limiting exposure to COVID-19 and preserving critical...
What is the current status of trial NCT04417270?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2020-06-12. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT04417270?
The interventions under investigation include: Freestyle Libre 14 day CGM system (DEVICE), Accuchek Inform II platform (DEVICE).
Who is sponsoring clinical trial NCT04417270?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.